Ok well lets see...
There are "no therapeutics are commercially available for the treatment of HFpEF.".
The initial results "suggesting a beneficial effect of PPS on the
myocardium".
Initial work out of the way...this sets us up for the next stage in this great new indication.
As I have posted (Where? Here ---->
Part 1 Heart
Part 2 Heart )
Why is this important?
Urgent and novel needs. Is this market big? Yep.
(Reference 1)
So much so that in my opinion they may actually go for this one first before ARDS for instance (my spec views).
Ok great result...why didn't the share price react?
1) It doesn't ever..ok sorry I'm being flippant...it will take time. P1...P2...and then P3.
2) People don't understand what this announcement is about...ie the mass market
As others have posted they just want a massive deal and/or P3 OA to be read out, nothing else seems to matter at this stage.
3) We are a ways off....this is accreditive to our pipeline...we will thank PAR for this not now but in years from now.
When you build a big building do you build it in a day?
No, the actual construction might take the better part of a year or two...but what about the planning, what about the site acquisition? Forget all that, what about getting funds for such a project and doing the feasibility? Council? Environmental impact statement? Objection filing and Architectural work just to name a few hurdles.
Ok ok so years...that's us too...
Wait for years and you will most likely garner the sweet fruit of the pipeline (my express opinions).
What did I think? Beaut...it sets us up over a number of years...its additive...its positive for a disease with "High mortality rates with 20 - 29% annually" 2 . Yes I understand the P value wasn't high...I wait for P1 in greater numbers for this real P value. At least this wasn't negative and the bar graphs didn't go backwards.
There isn't a lot out there that's safe for Heart Failure, our journey here just begins....
My views...you know what I must say - DYOR
Ref
1) https://drug-dev.com/heart-failure-market-to-soar-to-11-8-billion-by-2025/
2) https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02467799-135LU69QC1UNOQL9T73LEDSTBU/pdf?access_token=0007Cx3QASepe14mpPhSUGTfpcyJ
Ann: PAR REPORTS POSTIVE TOPLINE RESULTS IN HEART FAILURE MODEL, page-23
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
0.005(1.82%) |
Mkt cap ! $99.69M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 28.5¢ | 27.5¢ | $27.56K | 99.99K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1471 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 30554 | 6 |
View Market Depth
| Last trade - 12.06pm 11/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |